| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/MP.2011.146 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/mp.2011.146 |
| P932 | PMC publication ID | 3928114 |
| P698 | PubMed publication ID | 22083729 |
| P5875 | ResearchGate publication ID | 51798598 |
| P50 | author | Jian-ping Zhang | Q42842079 |
| Todd Lencz | Q37652358 | ||
| P2093 | author name string | A K Malhotra | |
| P2860 | cites work | Finding the missing heritability of complex diseases | Q22122198 |
| Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs | Q24630309 | ||
| A genomewide association study of citalopram response in major depressive disorder | Q24656746 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking | Q30432894 | ||
| Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. | Q33926334 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression | Q40638289 | ||
| Optimizing treatment with clozapine | Q41738250 | ||
| D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis | Q42056580 | ||
| Genome-wide pharmacogenetics of antidepressant response in the GENDEP project | Q42655084 | ||
| High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients | Q43294922 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism | Q44043068 | ||
| Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine | Q44407173 | ||
| Weight effects associated with antipsychotics: a comprehensive database analysis | Q44587936 | ||
| Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. | Q46267914 | ||
| Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study | Q46365535 | ||
| Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials | Q47241389 | ||
| Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis | Q47301630 | ||
| Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis | Q47402954 | ||
| Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. | Q51620290 | ||
| Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. | Q52217996 | ||
| Candidate Gene Analysis Identifies a Polymorphism inHLA-DQB1Associated With Clozapine-Induced Agranulocytosis | Q57382393 | ||
| Pharmacogenetics-based therapeutic recommendations — ready for clinical practice? | Q60486854 | ||
| Pharmacogenetics of lithium response in bipolar disorder | Q82292832 | ||
| Science and regulation. Regulating direct-to-consumer personal genome testing | Q85171244 | ||
| DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia | Q34061159 | ||
| Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. | Q34061511 | ||
| Antidepressant response and the serotonin transporter gene-linked polymorphic region | Q34088515 | ||
| PM frequencies of major CYPs in Asians and Caucasians | Q34228441 | ||
| The psychiatric GWAS consortium: big science comes to psychiatry | Q34350128 | ||
| CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages | Q34352560 | ||
| Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis | Q34415124 | ||
| Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment | Q34508743 | ||
| Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial | Q34586878 | ||
| Genomewide association studies: history, rationale, and prospects for psychiatric disorders | Q34606096 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese | Q34617803 | ||
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis | Q34624862 | ||
| Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction | Q34676533 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder | Q34871885 | ||
| Genomewide association study of movement-related adverse antipsychotic effects | Q35010386 | ||
| Half a century of antipsychotics and still a central role for dopamine D2 receptors | Q35595235 | ||
| A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression | Q35737324 | ||
| Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. | Q36356462 | ||
| Risperidone in the management of disruptive behavior disorders | Q36588152 | ||
| Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients | Q36673952 | ||
| Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research | Q36840610 | ||
| Genomics and the future of pharmacotherapy in psychiatry | Q36951758 | ||
| Pharmacogenomics: the promise of personalized medicine for CNS disorders. | Q37272534 | ||
| Medication adherence: a review of the literature and implications for clinical practice | Q37381596 | ||
| A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. | Q37536783 | ||
| The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. | Q37581138 | ||
| Personalized medicine for depression: can we match patients with treatments? | Q37789098 | ||
| Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses | Q37793826 | ||
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments | Q37848476 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psychiatry | Q7867 |
| P304 | page(s) | 760-769 | |
| P577 | publication date | 2011-11-15 | |
| P1433 | published in | Molecular Psychiatry | Q6895973 |
| P1476 | title | Pharmacogenetics in psychiatry: translating research into clinical practice | |
| P478 | volume | 17 |
| Q35846470 | "Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing |
| Q34255375 | 5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men. |
| Q34347951 | A genome-wide association study of a sustained pattern of antidepressant response |
| Q38172307 | Application of personalized medicine to chronic disease: a feasibility assessment |
| Q36148530 | Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis |
| Q38171656 | Behavior genetics: past, present, future |
| Q33715038 | Development of a Diverse Learning Experience for Diverse Psychiatry Resident Needs: A Four-Year Biological Psychiatry Curriculum Incorporating Principles of Neurobiology, Psychopharmacology, and Evidence-Based Practice |
| Q30490129 | GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder |
| Q38410122 | Genetics in child and adolescent psychiatry: methodological advances and conceptual issues |
| Q41873795 | Genetics of schizophrenia: What do we know? |
| Q34335425 | Genome-wide association study of medication adherence in chronic diseases in the korean population. |
| Q61809067 | Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method |
| Q33923615 | Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia |
| Q37541151 | Issues surrounding the health economic evaluation of genomic technologies |
| Q26853551 | Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls |
| Q38949040 | New Clinically Relevant Findings about Violence by People with Schizophrenia |
| Q41573540 | New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis |
| Q38162870 | Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine |
| Q38937776 | Personalized medicine in psychiatry |
| Q38842714 | Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis |
| Q38786972 | Pharmacogenetic Testing: Application in Mental Health Prescribing |
| Q38856372 | Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects |
| Q38154175 | Pharmacogenetics in schizophrenia: a review of clozapine studies |
| Q36539833 | Pharmacogenetics of antipsychotics: recent progress and methodological issues |
| Q37612442 | Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options |
| Q48241287 | SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. |
| Q38160942 | Safety profile of iloperidone in the treatment of schizophrenia |
| Q58609186 | Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis |
| Q38243174 | Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective. |
| Q38061501 | Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. |
| Q43214498 | The Need for Vigilance in the Marketing of Genomic Tests in Psychiatry |
| Q37452489 | The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration |
| Q38078013 | The implications of genomics on the nursing care of adults with neuropsychiatric conditions |
| Q38305701 | The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression |
| Q28079065 | Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics |
| Q50734208 | What is the role of pharmacogenetics in clinical psychiatry? |
Search more.